Zhong Huijuan Net Worth

Zhong Huijuan has an estimated net worth of $18.5 billion, according to Forbes Real-Time Billionaires, Zhong Huijuan profile (figures as of October 20, 2026). That is up from $1.6 billion in 2019.

Zhong Huijuan is a Chinese pharmaceutical executive who founded Hansoh Pharmaceutical and leads it as chair and CEO. The company is based in Lianyungang and makes oncology, psychoactive, antidiabetic, and other drugs. She moved into the drug business in 1995 after leaving her job as a chemistry teacher to run a new company that later became Hansoh. Over time, Hansoh grew from a small team into a major drugmaker and became publicly traded in Hong Kong in 2019.

Her wealth comes from building and holding a large stake in Hansoh Pharmaceutical. Early on, the business had about 10 employees, and by 1997 it had US$4.5 million in revenue. Zhong pushed spending on research and development, putting 5% of sales into R&D and later nearly 10% of revenue. Hansoh also expanded beyond China through licensing deals, including weight-loss treatments with Merck. Forbes put her net worth at $18.5 billion on its real-time billionaires tracker as of October 20, 2026.

How Zhong Huijuan built her fortune

Zhong Huijuan made her money in pharmaceuticals by founding and running Hansoh Pharmaceutical Group. She entered the industry in 1995, when a new company backed by Sun Piaoyang and a Hong Kong investor needed someone to lead it day to day. She took charge and helped shape its product mix, which included antibiotics, cancer treatments, psychotropic, endocrine, and gastrointestinal drugs. That focus on a broad drug portfolio helped turn Hansoh into a sizable business.

A big part of Hansoh's growth came from research and expansion. Zhong reinvested part of sales into R&D from the early years, starting at 5% and later reaching nearly 10% of revenue. The company is headquartered in Lianyungang and went public on the Hong Kong Stock Exchange in 2019. Hansoh has also signed licensing agreements with global drug companies, including billion-dollar deals with Merck tied to products such as weight-loss treatments, as it pushes further into international markets.

Forbes net worth track

Forbes has shown large swings in its estimate of Zhong's fortune over time. It listed her at $1.6 billion in 2019, then $14.6 billion in 2020, and $19.7 billion in 2021. After that, the estimate moved down to $8.1 billion in 2022 and $7.6 billion in 2023. Those changes line up with the value investors placed on Hansoh after its Hong Kong listing and as the company's position changed in public markets.

More recently, Forbes estimated Zhong at $7.7 billion in 2024 and $10.5 billion in 2025 before a sharp jump to $18.7 billion in 2026. The current Forbes real-time figure is $18.5 billion. Her money is closely tied to Hansoh, where she is the founder, chair, CEO, and majority shareholder with a 66% stake. The company’s public listing, drug portfolio, and international licensing activity are central to why her Forbes estimate has moved so much.